Optimal medical therapy is named as an intervention in 4 current clinical trials in our USA and China registers. 1 is recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Edwards Lifesciences (2). The most-studied condition is Tricuspid Valve Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145 · ClinicalTrials.gov ↗ · Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
|
Not applicable | Recruiting | Edwards Lifesciences | USA |
|
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907 · ClinicalTrials.gov ↗ · Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases
|
Not applicable | Not yet open | P+F Products + Features USA Inc. | USA |
|
Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction
NCT07678021 · ClinicalTrials.gov ↗ · Coronary Artery Disease (CAD)
|
Not applicable | Not yet open | China National Center for Cardiovascular Diseases | China |
|
TRISCEND II Pivotal Trial
NCT04482062 · ClinicalTrials.gov ↗ · Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
|
Not applicable | Active, closed | Edwards Lifesciences | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Edwards Lifesciences | 2 |
| P+F Products + Features USA Inc. | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA and China registers name Optimal medical therapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Edwards Lifesciences (2), P+F Products + Features USA Inc (1) and China National Center for Cardiovascular Diseases (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Optimal medical therapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Optimal medical therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Optimal medical therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.